POINT’s CanSEEK™ has been sub-licensed from both Bach Biosciences and Avacta,
which has branded the technology as pre | CISION (an Avacta trademark)
Lantheus and POINT Biopharma have announced a strategic collaboration and exclusive license agreements for the commercialization of PNT2002 and PNT2003
mCRPC = Metastatic Castration Resistant Prostate Cancer, PSMA = Prostate Specific Membrane Antigen, SSTR = somatostatin receptors, FAP-α = Fibrolast Activation Protein -α
Toxicity caused by off-target delivery is a longstanding concern of cancer therapies. POINT’s CanSEEK™ technology aims to minimize toxicity caused by off-target delivery by only activating a radiopharmaceuticals' targeting moiety, such as its ligand, after it has encountered FAP-α in the tumor microenvironment (TME).
Prostate cancer is one of the most common types of cancer in men. While many prostate cancers grow slowly and are confined to the prostate gland, some are metastatic and spread throughout the body.
PNT2002 is a PSMA targeted radioligand in a Phase 3 trial for an aggressive form of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC).
PNT2001 is an early stage, next-generation PSMA targeted radioligand addressing toxicity concerns by focusing on increased tumor enrichment.
Neuroendocrine tumors, also known as NETs, are neoplasms that arise from cells of the endocrine and nervous systems. They most commonly occur in the digestive tract, lungs, pancreas or lungs.
PNT2003 is a somatostatin-targeted radioligand therapy in development for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors.